FDA
-
-
-
-
-
-
-
Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44
-
-
-
-
-
-
-
Raymond James Reiterates Strong Buy Rating on Avidity Biosciences (RNA)
-
-
-
-
-
-
-
Avidity gets FDA breakthrough status for muscle disease treatment
-
-
-
-
-
-
-
Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE⢠Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Partici
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Avidity Biosciences (RNA)
-
-
-
-
-
-
-
7 top biotech picks for 2025 according to Wells Fargo
-
-
-
-
-
-
-
TD Cowen Reiterates Buy Rating on Avidity Biosciences (RNA)
-
325,893 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

